Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flumetramide SCHEMBL9576017 | 1.00 | PRKAB2 (0.43) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL28535518 | 0.85 | HTR1A (0.42) | HTR1APARP1PARP2HTR2C | |
| SCHEMBL2299466 | 0.82 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2296542 | 0.82 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL18742045 | 0.82 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15301051 | 0.80 | PRKAB2 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL8192120 | 0.80 | PRKAB2 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL25181383 | 0.79 | PRKAB2 (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL21779357 | 0.79 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL18741907 | 0.79 | HTR1A (0.39) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-204969991-U | Dual -use multi -functional quick detach both shoulders knapsack | JIHUA 3502 PROFESSIONAL GARMENT CO LTD | 2016-01-20 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-1478648-B1 | PHOSPHORUS-CONTAINING COMPOUNDS AND USES THEREOF | ARIAD PHARMA INC (US) | 2014-04-30 | — | — | EP | claimed |
| US-8539862-B1 | Buckle release tool | MiiG Enterprises, Inc. (US) | 2013-09-24 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| CN-1646537-A | Phosphorus-containing compounds and their use | ARIAD GENE THERAPEUTICS INC (US) | 2005-07-27 | — | — | CN | claimed |
| US-20050032825-A1 | Phosphorus-containing compounds and uses thereof | MEDINOL LTD. (IL) | 2005-02-10 | — | — | US | claimed |
| EP-1478648-A2 | PHOSPHORUS-CONTAINING COMPOUNDS USES THEREOF | ARIAD GENE THERAPEUTICS, INC. (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040073024-A1 | Phosphorus-containing compounds and uses thereof | ARIAD GENE THERAPEUTICS, INC. | 2004-04-15 | — | — | US | claimed |
| US-20030220297-A1 | Phosphorus-containing compounds and uses thereof | ARIAD GENE THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003064383-A2 | PHOSPHORUS-CONTAINING COMPOUNDS & USES THEREOF | ARIAD GENE THERAPEUTICS, INC. (US) | 2003-08-07 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220297-A1 | Phosphorus-containing compounds and uses thereof | NR5A2, NR2C2, NR2E1 | PRKAB2 2121/4885PRKAG1 2455/4885PRKAA2 1944/4885 |
| US-20040073024-A1 | Phosphorus-containing compounds and uses thereof | NR5A2, VDR, NR5A1 | PRKAB2 1436/4885PRKAG1 1949/4885PRKAA2 1562/4885 |
| US-20050032825-A1 | Phosphorus-containing compounds and uses thereof | NR5A2, NR2E3, VDR | PRKAB2 1196/4885PRKAG1 1905/4885PRKAA2 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.